MX9308015A - 6-azaandrostenonas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen. - Google Patents

6-azaandrostenonas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen.

Info

Publication number
MX9308015A
MX9308015A MX9308015A MX9308015A MX9308015A MX 9308015 A MX9308015 A MX 9308015A MX 9308015 A MX9308015 A MX 9308015A MX 9308015 A MX9308015 A MX 9308015A MX 9308015 A MX9308015 A MX 9308015A
Authority
MX
Mexico
Prior art keywords
androgen
substituted
azaandrostenonas
contain
preparation
Prior art date
Application number
MX9308015A
Other languages
English (en)
Inventor
Curt Dale Haffner
Patrick Reed Maloney
Robert Carl Andrews
Cynthia Markert Cribbs
Stephen Vernon Frye
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of MX9308015A publication Critical patent/MX9308015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a ciertas 6-azaandrost-4-en3-onas sustituidas en la posición 17 ß sustituidas y a su uso como inhibidores de la reductasa de la 5Ó-testoterona. Los andrógenos son responsables de muchas funciones fisiológicastanto en machos como en hembras. La acción del andrógeno está mediada por los receptores de la hormona intracelular, específicos, expresados en las células sensibles al andrógeno. La testosterona, el andrógeno de circulación principal, es secretada por las células de Leydig de las testes o testículos, bajo la estimulación de la hormona luteinizante derivada de la pituitaria (LH).
MX9308015A 1992-12-18 1993-12-15 6-azaandrostenonas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen. MX9308015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99393092A 1992-12-18 1992-12-18
US8066593A 1993-06-18 1993-06-18

Publications (1)

Publication Number Publication Date
MX9308015A true MX9308015A (es) 1994-08-31

Family

ID=26763785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9308015A MX9308015A (es) 1992-12-18 1993-12-15 6-azaandrostenonas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen.

Country Status (24)

Country Link
EP (1) EP0674651B1 (es)
JP (1) JPH08504825A (es)
CN (1) CN1095383A (es)
AP (1) AP459A (es)
AT (1) ATE172738T1 (es)
AU (1) AU673899B2 (es)
BG (1) BG99729A (es)
CA (1) CA2152053A1 (es)
CZ (1) CZ157695A3 (es)
DE (1) DE69321849D1 (es)
FI (1) FI953009A (es)
HU (1) HUT72083A (es)
IL (1) IL108073A0 (es)
IS (1) IS4106A (es)
LV (1) LV10958B (es)
MX (1) MX9308015A (es)
NO (1) NO952402L (es)
NZ (1) NZ261415A (es)
OA (1) OA10167A (es)
PL (1) PL314532A1 (es)
SI (1) SI9300665A (es)
SK (1) SK79495A3 (es)
TW (1) TW293824B (es)
WO (1) WO1994014833A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5516779A (en) * 1994-06-08 1996-05-14 Merck & Co., Inc. 17β-substituted-6-azasteroid derivatives useful as 5α-reductase inhibitors
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
WO1997014418A1 (en) * 1995-10-19 1997-04-24 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
ATE498600T1 (de) 2003-04-15 2011-03-15 Aquinox Pharmaceuticals Inc Inden derivate als pharmazeutika
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
MX2015012111A (es) 2013-03-14 2016-05-05 Aquinox Pharmaceuticals Canada Inc Moduladores de ship1 y métodos relacionados con éstos.
RU2015143675A (ru) 2013-03-14 2017-04-27 Экуинокс Фармасьютикалз (Кэнэда) Инк. Ship1 модуляторы и относящиеся к ним способы
CN107787315A (zh) 2015-06-26 2018-03-09 阿奎诺克斯药物（加拿大）公司 (1s,3s,4r)‑4‑((3as,4r,5s,7as)‑4‑(氨甲基)‑7a‑甲基‑1‑亚甲基八氢‑1h‑茚‑5‑基)‑3‑(羟甲基)‑4‑甲基环己醇的乙酸盐的结晶固体形式
AU2017209430A1 (en) 2016-01-20 2018-07-12 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
BR112018072255B1 (pt) * 2016-04-29 2024-02-06 The Research Foundation For The State University Of New York Azasteroides para tratamento de tuberculose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013124A1 (en) * 1991-12-20 1993-07-08 Glaxo Inc. Inhibitors of 5-alpha-testosterone reductase
US5438061A (en) * 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors

Also Published As

Publication number Publication date
JPH08504825A (ja) 1996-05-28
IL108073A0 (en) 1994-04-12
SI9300665A (en) 1994-06-30
PL314532A1 (en) 1996-09-16
LV10958A (lv) 1995-12-20
LV10958B (en) 1996-10-20
BG99729A (en) 1996-01-31
EP0674651A1 (en) 1995-10-04
IS4106A (is) 1994-06-19
WO1994014833A3 (en) 1994-09-29
NO952402L (no) 1995-08-16
NO952402D0 (no) 1995-06-16
AU6015094A (en) 1994-07-19
DE69321849D1 (de) 1998-12-03
CA2152053A1 (en) 1994-07-07
WO1994014833A2 (en) 1994-07-07
AP9300599A0 (en) 1994-01-31
ATE172738T1 (de) 1998-11-15
CZ157695A3 (en) 1995-12-13
EP0674651B1 (en) 1998-10-28
CN1095383A (zh) 1994-11-23
OA10167A (en) 1996-12-18
TW293824B (es) 1996-12-21
HU9501775D0 (en) 1995-08-28
FI953009A (fi) 1995-08-15
AP459A (en) 1996-02-14
HUT72083A (en) 1996-03-28
AU673899B2 (en) 1996-11-28
SK79495A3 (en) 1995-11-08
FI953009A0 (fi) 1995-06-16
NZ261415A (en) 1997-03-24

Similar Documents

Publication Publication Date Title
MX9308015A (es) 6-azaandrostenonas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
Poyet et al. Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate
FERRÉ et al. Role of hCG in regulation of the fetal zone of the human fetal adrenal gland
Naftolin et al. Aromatization of androstenedione by the anterior hypothalamus of adult male and female rats
Nimrod et al. A synergistic effect of androgen on the stimulation of progesterone secretion by FSH in cultured rat granulosa cells
EP1084569B1 (de) Androgene in kombination mit gestagene zum ausgleich eines testosteron-defizits mit schutz der prostata
Polzonetti-Magni et al. Plasma sex hormones and post-reproductive period in the green frog, Rana esculenta complex
ES2176190T3 (es) Inhibidores de la actividad de esteroides sexuales.
ATE322271T1 (de) Therapeutische verwendungen von dehydroepiandrosteron zur behandlung von verminderter libido und osteoporose
DE1017748B (de) Praeparat zur Pflege der menschlichen Haut
Greenberg et al. Parathyroid hormone secretion: effect of estradiol and progesterone
De Kretser The regulation of male fertility the state of the art and future possibilities
Flerkó et al. Pituitary hypertrophy after anterior hypothalamic lesion
Celasco et al. Biological profile of cortexolone 17a-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist
Gross et al. Luteinizing hormone and follicle‐stimulating hormone production in the pars tuberalis of hypophysectomized rats
Schoonen et al. Steroidogenesis in the testes and seminal vesicles of spawning and non-spawning African catfish, Clarias gariepinus
Zaffaroni The effect of alkyl-and electronegative-group substitution on steroidal hormone activity
Asahina et al. Effects of various androgens on the formation of papillary processes on the anal fin rays in the female medaka Oryzias latipes
KAUFMAN et al. Autonomous ovarian hyperfunction followed by gonadotrophin‐dependent puberty in McCune‐Albright syndrome
DE60127103T2 (de) Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend
Greenblatt et al. Pituitary-ovarian relationships
DE1518994A1 (de) Verfahren zur Herstellung von neuen Beta,10Alpha-Steroiden
Huis In't Veld et al. The Influence of 17Α-Methyl-19-Nortestosterone on the Endocrine Function of the Adrenal Cortex
Debeljuk et al. Pituitary gonadotrophin activity in male rats with damage of the germinal epithelium induced by busulphan
Lau et al. Steroids in the rete testis fluid of fertile male rabbits